What Has Been the Progress and Growth of the Hyperuricemia Drugs Market in Recent Years?
The hyperuricemia drugs market has seen considerable growth due to a variety of factors.
• There has been a robust growth in the market size of hyperuricemia drugs in recent times. The market is projected to increase from $4.75 billion in 2024 to $5.16 billion in 2025, marking a compound annual growth rate (CAGR) of 8.5%.
The growth in the past period comes from factors like the escalating occurrence of gout, limited choices for treatment, an expanding elderly population, inactive lifestyles, and heightened consciousness about hyperuricemia.
What Can Be Expected from the Hyperuricemia Drugs Market Size?
The hyperuricemia drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market for hyperuricemia drugs is projected to experience substantial growth in the forthcoming years. The market is predicted to increase to $7.07 $ billion by 2029, boasting a compound annual growth rate (CAGR) of 8.2%.
This predicted surge during the forecast period can be credited to the escalating prevalence of chronic kidney disease, an intensified attention on early diagnosis, the increasing necessity for personalized medication, advancements made in creating new drug formulations, and escalating health care spending. The forecast period is expected to see key trends such as an increasing emphasis on precision medication, growing preference for combination therapies, innovations in non-invasive treatment methods, increased focus on the safety and efficiency of drugs, and improvements in the field of pharmacogenomics.
What Are the Critical Driver Fuelling The Hyperuricemia Drugs Market's Growth?
The hyperuricemia drug market is predicted to flourish due to the growing occurrence of hyperuricemia and gout. Hyperuricemia, a condition where uric acid levels in the blood are excessively high, can lead to gout, a form of arthritis that causes severe pain due to urate crystal accumulation in the joints. Factors such as genetic susceptibility, dietary preferences (particularly a high purine diet), obesity, kidney functionality, lifestyle behaviors (like alcohol use and dehydration), certain medicines, and long-term diseases like hypertension and diabetes, impact the frequencies of hyperuricemia and gout. Medication for hyperuricemia is crucial in managing uric acid levels to hinder the onset and worsening of hyperuricemia and gout, as it minimizes uric acid buildup and eases related symptoms. For example, data from The Lancet, a UK-based general medical journal, in July 2024 stated that globally, gout was 3.26 times more common in men than women in 2020 and its prevalence increased with age, projecting around 95.8 million prevalent cases by 2050. Consequently, the escalating occurrence of hyperuricemia and gout is fueling the expansion of the hyperuricemia drug market.
How Is The Hyperuricemia Drugs Market segmented?
The hyperuricemia drugsmarket covered in this report is segmented –
1) By Type: Asymptomatic Hyperuricemia, Symptomatic Hyperuricemia, Other Types
2) By Drugs: Nonsteroidal Anti-Inflammatory Drugs, Xanthine Oxidase Inhibitors, Selective Uric Acid Reabsorption Inhibitor (SURI), Uricosuric Agents, Other Drugs
3) By Diseases: Gout, Kidney Stone, Other Diseases
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Asymptomatic Hyperuricemia: Uric Acid Lowering Agents, Lifestyle Modification Supplements
2) By Symptomatic Hyperuricemia: Anti-Inflammatory Drugs, Uric Acid Inhibitors, Corticosteroids
3) By Other Types: Combination Therapy, Supportive Care Medications, Dietary Supplements
Pre-Book The Hyperuricemia Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Hyperuricemia Drugs Industry?
A strong focus on developing cutting-edge products has been seen from key companies in the hyperuricemia drug market. They aim at creating therapeutic equivalent generic versions of drugs to offer a low-cost alternative that may increase accessibility to gout treatment for patients. A therapeutic equivalent generic version contains the identical active ingredient as its brand-name counterparts, possesses the same dosage form, and is anticipated to showcase similar clinical effects and safety profiles. For example, in January 2024, the US health regulator gave approval to Lupin, a pharmaceutical company in India, for the production of Febuxostat Tablets (40 mg and 80 mg) and Varenicline Tablets (0.5 mg and 1 mg). By offering these generic drugs which are purposed for treating hyperuricemia (Febuxostat) and assisting smoking cessation (Varenicline), Lupin is striving to improve access to necessary medications. At the same time, it aims to capture a portion of the US pharmaceutical market and offers patients cost-efficient alternatives for their healthcare demands.
Who Are the Key Players In The Hyperuricemia Drugs Market?
Major companies operating in the hyperuricemia drugs market are:
• Pfizer Inc.
• Merck & Co.
• Bayer AG
• Sanofi SA
• Myers Squibb Bristol Company
• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline PLC
• Roche Holdings Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceuticals
• Regeneron Pharmaceuticals Inc.
• Teijin Pharma Limited
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals Inc.
• Glenmark Pharmaceuticals Ltd.
• Kissei Pharmaceutical Co. Ltd.
• Himalaya Wellness Company
• Fuji Yakuhin Co. Ltd.
What Is The Most Dominant Region In The Hyperuricemia Drugs Market?
North America was the largest region in the hyperuricemia drugs market in 2024. The regions covered in the hyperuricemia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
